Validation of the HCC-MELD for dropout probability in patients with small hepatocellular carcinoma undergoing locoregional therapy

Clinical Transplantation

Volumn 22, Issue 4, 2008, Pages 469-475

  Huo, Teh La ^a,b   Huang, Yi Hsiang ^a,b   Su, Chien Wei ^a,b   Lin, Han Chieh ^a,b   Chiang, Jen Huei ^a,b   Chiou, Yi You ^a,b   Huo, Samantha C ^c   Lee, Pui Ching ^a   Lee, Shou Dong ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c WASHINGTON UNIVERSITY   (United States)

Author keywords

Hepatocellular carcinoma; Liver cirrhosis; Liver transplantation; Model for end stage liver disease

Indexed keywords

ACETIC ACID; ALCOHOL;

ACCURACY; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER THERAPY; CATHETER ABLATION; CHEMOEMBOLIZATION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HEPATOCELLULAR CARCINOMA MODEL FOR END-STAGE LIVER DISEASE; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROBABILITY; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; TUMOR GROWTH; VALIDATION PROCESS;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; DECISION SUPPORT TECHNIQUES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE RATIONING; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASM STAGING; PATIENT DROPOUTS; PATIENT SELECTION; PROBABILITY; PROSPECTIVE STUDIES;

EID: 48249132816     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2008.00811.x     Document Type: Article

References (31)

1. El-Serag HB, D avila JA, P etersen NJ et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: An update. Ann Intern Med 2003: 139: 817.
2. Pompili M, Mirante VG, R ondinaraG et al. Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: Assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transpl 2005: 11: 1117.
3. Livraghi T, Meloni F, Morabito A et al. Multimodal image-guided tailored therapy of early and intermediate hepatocellular carcinoma: Long-term survival in the experience of a single radiologic referral center. Liver Transpl 2004: 2 (Suppl. 1): S98.
4. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996: 334: 693.
5. Freeman RB. Overview of the MELD/PELD system of liver allocation indications for liver transplantation in the MELD era: Evidence-based patient selection. Liver Transpl 2004: 10 (Suppl. 2): S2.
6. de la Mata M, Cuende N, Huet J et al. Model for end-stage liver disease score-based allocation of donors for liver transplantation: A Spanish multicenter experience. Transplantation 2006: 82: 1429.
7. Freeman RB, Edwards EB, Harper AM. Waiting list removal rates among patients with chronic and malignant liver diseases. Am J Transplant 2006: 6: 1416.
8. Huo TI, Wu JC, Lin HC et al. Determination of the optimal model for end-stage liver disease score in patients with small hepatocellular carcinoma undergoing loco-regional therapy. Liver Transpl 2004: 10: 1507.
9. Huo TI, Huang YH, Wu JC et al. Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for hepatocellular carcinoma in cirrhotic patients: A prospective study. Scand J Gastroenterol 2003: 38: 770.
10. Lin SM, Lin CJ, Lin CC et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or = 4cm. Gastroenterology 2004: 127: 1714.
11. Huo TI, Huang YH, Lin HC et al. Proposal of a modified Cancer of the Liver Italian Program staging system based on the model for end-stage liver disease for patients with hepatocellular carcinoma undergoing loco-regional therapy. Am J Gastroenterol 2006: 101: 975.
12. Huo TI, Wu JC, Lee PC et al. Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: A prospective study. Liver Int 2004: 24: 210.
13. Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005: 42: 1208.
14. Freeman RB Jr, Wiesner RH, Roberts JP et al. Improving liver allocation: MELD and PELD. Am J Transplant 2004: 4 (Suppl. 9): 114.
15. Wong LL, Tsai N, Limm W et al. Liver transplant for hepatocellular cancer: A treatment for the select few. Clin Transplant 2004: 18: 205.
16. Ravaioli M, Grazi GL, Ercolani G et al. Liver allocation for hepatocellular carcinoma: A European Center policy in the pre-MELD era. Transplantation 2006: 81: 525.
17. Fisher RA, Maluf D, Cotterell AH et al. Non-resective ablation therapy for hepatocellular carcinoma: Effectiveness measured by intention-to-treat and dropout from liver transplant waiting list. Clin Transplant 2004: 18: 502.
18. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation. Hepatology 1999: 30: 1434.
19. Maddala YK, Stadheim L, Andrews JC et al. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: Outcome with chemoembolization. Liver Transpl 2004: 10: 449.
20. Graziadei IW, Sandmueller H, Waldenberger P et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003: 9: 557.
21. Yao FY, Bass NM, Nikolai B et al. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: Implications for the current organ allocation policy. Liver Transpl 2003: 9: 684.
22. Yamashiki N, Gaynor JJ, Kato T et al. Competing risks analysis of predictors of delisting owing to tumor progression in liver transplant candidates with hepatocellular carcinoma. Am J Transplant 2004: 4: 774.
23. Lu DS, Yu NC, Raman SS et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 2005: 41: 1130.
24. Llovet JM, Mas X, Aponte JJ et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 2002: 50: 123.
25. Huo TI, Huang YH, Wu JC et al. Induction of complete tumor necrosis may reduce intrahepatic metastasis and prolong survival in patients with hepatocellular carcinoma undergoing locoregional therapy: A prospective study. Ann Oncol 2004: 15: 775.
26. Martin AP, Goldstein RM, Dempster J et al. Radiofrequency thermal ablation of hepatocellular carcinoma before liver transplantation - a clinical and histological examination. Clin Transplant 2006: 20: 695.
27. Shetty K, Timmins K, Brensinger C et al. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl 2004: 10: 911.
28. Axelrod D, Koffron A, Kulik L et al. Living donor liver transplant for malignancy. Transplantation 2005: 79: 363.
29. Chan HL, Chim AM, Lau JT et al. Evaluation of model for end-stage liver disease for prediction of mortality in decompensated chronic hepatitis B. Am J Gastroenterol 2006: 101: 1516.
30. Huo TI, Lee PC, Huang YH et al. The sequential changes of the model for end-stage liver disease score correlate with the severity of liver cirrhosis in patients with hepatocellular carcinoma undergoing locoregional therapy. J Clin Gastroenterol 2006: 40: 543.
31. Huo TI, Lin HC, Huang YH et al. The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapy. Cancer 2006: 107: 141.